Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by bringon10baggeron Mar 25, 2021 1:24pm
179 Views
Post# 32876287

RE:RE:Expensive Pfizer drug for OA likely to fail

RE:RE:Expensive Pfizer drug for OA likely to failThat's welcoming to understand the FDA and their positioning for improvement in treatment over existing NSAID, and knowing the qualities of  ATB-346 over existing NSAID things look very encouraging....SUPER GI Safe over existing, smaller dosing for better WOMAC results  and could be less than already established and notthing else any worse than existing NSAID's. THAT'S ENCOURAGING.........



Straylight wrote: Nice article. Couple good quotes about that drug from the link:

"Although FDA said tanezumab proved to be effective, its effect size “is modest, and there is no convincing evidence of a superior efficacy of tanezumab over NSAIDs.”

"In addition, the agency said tanezumab is associated with an elevated risk of requiring a total joint replacement, as observed in two of the three post-2015 clinical studies, with evidence of dose response. There is also evidence that the risk for developing joint destruction is 2- to 3-fold higher if NSAIDs and tanezumab are used together, FDA said."


<< Previous
Bullboard Posts
Next >>